RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:466722

Autosomal recessive spastic paraplegia type 77

high confidenceDisorder

Also known as: SPG77

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

27

41.8th percentile

Trials

0

Interventional, condition-specific

Researchers

252

Distinct authors in sample

Gene link

FARS2

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

spastic paraplegia type 77 is a rare, pure or complex spastic paraplegia characterized by an infancy to childhood onset of slowly lower limb spasticity, delayed motor milestones, gait disturbances, hyperreflexia and various muscle abnormalities, including weakness, , intention tremor and amyotrophy. Ocular abnormalities (e.g. strabismus, ptosis) and other neurological abnormalities, such as dysarthria, and extensor plantar responses, may also be associated.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

FARS2 hereditary spastic paraplegia · hereditary spastic paraplegia caused by mutation in FARS2 · hereditary spastic paraplegia type 77 · spastic paraplegia 77, autosomal recessive

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — FARS2

  2. LiteraturePresent

    27 matched papers (27 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 102 for broader category paraplegia

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (FARS2).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

27

27 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

27 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

27 in the last 10 years · high confidence · 41.8th percentile (publications denominator)

Phrase hits: 27 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

252

Distinct author names in 27 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bassi MT2 papers · 2025

    Laboratory of Medical Genetics, Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, 23842 Lecco, Italy.

    Papers in Europe PMC
  2. 02
    Chen WJ2 papers · 2024

    Department of Neurology and Institute of Neurology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China. wanjinchen75@fjmu.edu.cn.

    Papers in Europe PMC
  3. 03
    Graham JM2 papers · 2021

    Department of Pediatrics, Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, USA.

    Papers in Europe PMC
  4. 04
    Lin X2 papers · 2024

    Department of Neurology and Institute of Neurology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China. linxiang1988@fjmu.edu.cn.

    Papers in Europe PMC
  5. 05
    Pierson TM2 papers · 2021

    Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, USA.

    Papers in Europe PMC
  6. 06
    Safka Brozkova D2 papers · 2026

    DNA Laboratory, Department of Paediatric Neurology, 2nd Faculty of Medicine Charles University and University Hospital Motol, Prague, Czech Republic.

    Papers in Europe PMC
  7. 07
    Santorelli FM2 papers · 2025

    Molecular Medicine Unit, IRCCS Fondazione Stella Maris, Pisa, Italy.

    Papers in Europe PMC
  8. 08
    Seeman P2 papers · 2021

    DNA Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

    Papers in Europe PMC
  9. 09
    Uhrova Meszarosova A2 papers · 2026

    DNA Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

    Papers in Europe PMC
  10. 10
    Wang N2 papers · 2024

    Department of Neurology and Institute of Neurology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 102 trials are registered for paraplegia, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

102 interventional trials matched paraplegia, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: paraplegia

102

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Autosomal recessive spastic paraplegia type 77" OR "SPG77" OR "FARS2 hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in FARS2" OR "hereditary spastic paraplegia type 77" OR "spastic paraplegia 77, autosomal recessive"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal recessive spastic paraplegia type 77" OR "SPG77" OR "FARS2 hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in FARS2" OR "hereditary spastic paraplegia type 77" OR "spastic paraplegia 77, autosomal recessive" OR "FARS2"

Recall-expansion terms: FARS2

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"paraplegia"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T16:59:25.625Z